Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Open Access

Table S12 from NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MIMilad IbrahimIIIrineu Illa-BochacaGJGeorge Jour

Discussion

Loading...

Member takes

Overview

Analysis shows enhanced EGFR activity and sensitivity to cetuximab in NF1-mutant melanoma, indicating potential therapeutic targets.

Key Points

  • NF1 loss enhances EGFR activation and sensitivity to treatment with cetuximab in melanoma.
  • Pathway analysis identified differentially expressed genes (DEGs) between cetuximab and IgG in PDX models.
  • Findings point to the importance of NF1 in melanoma pathology and possible treatment strategies.
  • The results suggest targeting EGFR could be a viable option for patients with NF1-mutant melanoma.

Cite This Study

Ibrahim et al. (2025) studied this question.

synapsesocial.com/papers/68c23a2cb210217d6477fb63https://doi.org/10.1158/0008-5472.30029870
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Table S5 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma2025
  2. 2Table S9 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma2025
  3. 3Table S2 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma2025
  4. 4Table S3 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma2025
  5. 5Table S8 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma2025